Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Co.'s primary product candidate, Twyneo®, is a once-daily, non-antibiotic topical cream that it is developing for the treatment of acne vulgaris. Co.'s second branded product candidate is Epsolay®, a potential treatment for subtype II rosacea. Co.'s other branded product candidates are SGT-210, a potential treatment of palmoplantar keratoderma. Co. is also pre-clinically testing erlotinib, tapinarof and roflumilast in various new pharmaceutical indications. We show 3 historical shares outstanding datapoints in our SLGL shares outstanding history coverage, used to compute SLGL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SLGL market cap history over the course of time is important for investors
interested in comparing SLGL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SLGL versus a peer is one thing; comparing
SLGL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SLGL can fluctuate over the course of history.
With this page we aim to empower investors researching SLGL by allowing them to research the SLGL market cap history. |
Free SLGL Email Alerts:
Video: The Importance of Market Cap
